Evaxion Biotech AS (EVAX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$2.80

+0.00 (+0.00%)

Market Cap: $25.26M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

67%(16/24)

Avg Surprise

-185.27%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.01

Range$-0.01 - $-0.01

1 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$-0.010.0%

60d ago$-0.010.0%

30d ago$-0.010.0%

7d ago$-0.010.0%

Current$-0.01

Revenue Consensus

Range$0 - $0

3 analysts

Period ending Dec 31, 2026

EPS Consensus$0.21

Range$0.21 - $0.21

2 analysts

Revenue Consensus

Range$0 - $0

4 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.21	$0.21 - $0.21	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.01	$-0.01 - $-0.01	-	-	1	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 13, 2026Reported Aug 13	$-0.50	$-0.01	$-0.01 - $-0.01	-4900.00%	Miss	1	No revisions (30d)	+50.0%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.01	$-0.01	-	+0.00%	Beat	2	1 0 30d	+98.0%
Dec 31, 2025Dec 25 Reported Mar 5, 2026Reported Mar 5	$-0.01	$-0.01	$-0.01 - $-0.01	+0.00%	Beat	1	1 1 30d	+85.7%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$0.01	$-0.01	$-0.01 - $-0.01	+200.00%	Beat	1	No revisions (30d)	+105.0%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-1.00	$-0.58	$-0.66 - $-0.50	-72.41%	Miss	2	0 2 30d	+83.3%
Mar 31, 2025Mar 25 Reported May 27, 2025Reported May 27	$-0.50	$-0.70	$-0.76 - $-0.65	+28.57%	Beat	2	0 1 30d	-266.7%
Dec 31, 2024Dec 24 Reported Mar 26, 2025Reported Mar 26	$-0.07	N/A	-	+53.33%	Beat	3	1 0 30d	+99.1%
Sep 30, 2024Sep 24 Reported Oct 31, 2024Reported Oct 31	$-0.20	N/A	-	+66.67%	Beat	3	1 0 30d	+98.1%
Jun 30, 2024Jun 24 Reported Aug 14, 2024Reported Aug 14	$-6.00	$-3.50	$-3.81 - $-3.19	-71.43%	Miss	2	No revisions (30d)	+42.9%
Mar 31, 2024Mar 24 Reported May 28, 2024Reported May 28	$0.30	$-0.56	$-0.99 - $-0.12	+153.57%	Beat	2	No revisions (30d)	+102.1%
Dec 31, 2023Dec 23 Reported Mar 27, 2024Reported Mar 27	$-8.00	$-8.00	$-8.00 - $-8.00	+0.00%	Beat	2	No revisions (30d)	-175.9%
Sep 30, 2023Sep 23 Reported Dec 19, 2023Reported Dec 19	$-10.50	$-9.75	$-9.75 - $-9.75	-7.69%	Miss	0	No revisions (30d)	+12.5%
Jun 30, 2023Jun 23 Reported Aug 18, 2023Reported Aug 18	$-10.50	$-10.75	$-10.76 - $-10.75	+2.33%	Beat	2	No revisions (30d)	+12.5%
Mar 31, 2023Mar 23 Reported Apr 27, 2023Reported Apr 27	$-14.50	$-13.17	$-13.20 - $-13.14	-10.10%	Miss	2	No revisions (30d)	-45.0%
Dec 31, 2022Dec 22 Reported Dec 31, 2022Reported Dec 31	$-2.90	$-2.63	$-2.63 - $-2.63	-10.27%	Miss	0	No revisions (30d)	-1060.0%
Nov 14, 2022Nov 22 Reported Nov 14, 2022Reported Nov 14	$-12.00	$-17.00	-	+29.41%	Beat	-	-	+38.5%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-12.00	$-13.33	$-13.40 - $-13.28	+9.98%	Beat	3	No revisions (30d)	+11.1%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-10.00	$-15.00	$-15.03 - $-14.98	+33.33%	Beat	3	No revisions (30d)	+44.4%
Mar 31, 2022Mar 22 Reported May 11, 2022Reported May 11	$-0.25	$-0.33	$-0.39 - $-0.24	+24.24%	Beat	3	No revisions (30d)	+97.8%
Dec 31, 2021Dec 21 Reported Mar 22, 2022Reported Mar 22	$-19.50	$-15.00	$-15.01 - $-14.99	-30.00%	Miss	3	No revisions (30d)	-10163.2%
Sep 30, 2021Sep 21 Reported Nov 9, 2021Reported Nov 9	$-13.50	$-17.25	$-17.27 - $-17.23	+21.74%	Beat	3	No revisions (30d)	-36.3%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$-18.00	$-14.75	$-14.76 - $-14.75	-22.03%	Miss	3	No revisions (30d)	-137.3%
Mar 31, 2021Mar 21 Reported Apr 6, 2021Reported Apr 6	$-11.50	$-16.50	$-16.53 - $-16.47	+30.30%	Beat	2	No revisions (30d)	-78.1%
Dec 31, 2020Dec 20 Reported Jan 25, 2021Reported Jan 25	$-0.19	$-0.25	$-0.25 - $-0.25	+24.00%	Beat	1	No revisions (30d)	+97.4%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-9.90	N/A	-	N/A	Beat	-	-	-
Jun 30, 2020Jun 20 Reported Jul 5, 2020Reported Jul 5	$-7.58	N/A	-	N/A	Beat	-	-	-
Mar 31, 2020Mar 20 Reported Apr 5, 2020Reported Apr 5	$-6.46	N/A	-	N/A	Beat	-	-	-
Dec 31, 2019Dec 19 Reported Dec 31, 2019Reported Dec 31	$-7.33	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-5.49	EV/EBITDA	N/A
Price/FCF	-0.07x	FCF Yield	-1505.13%
Profitability
Profit Margin	-115.50%	Operating Margin	-116.00%
ROE	-109.90%	ROIC	-79.46%
Financial Health
Debt/Equity	0.56x	Interest Coverage	-4.40x
Current Ratio	5.06x	Quick Ratio	5.06x
Trading Statistics
Beta	0.51	Avg Volume	45.53K
52-Week High	$9.50	52-Week Low	$2.72

Technical Indicators Dashboard

Moving Averages

SMA 10$3.02

SMA 20$3.14

SMA 50$3.14

SMA 200$3.59

EMA 10$2.97

EMA 20$3.06

EMA 50$3.14

EMA 200$3.47

MACD

Line: -0.08Signal: -0.03Hist: -0.05

ADX

ADX: 16.0+DI: 15.5-DI: 22.9

Aroon & PSAR

Aroon Up56.0

Aroon Down92.0

PSAR$3.26

Bollinger Bands

Upper Band$3.48

Lower Band$2.79

%B Position2215%(Upper)

Band Width0.01

RSI (14-Day)

Neutral

32.2

Momentum Oscillators

Stoch %K10.6

Stoch %D8.7

Williams %R-87.3

ROC (10d)-11.9%

Momentum-0.38

CCI (20d)-176.2

MFI (14d)12.5

Volatility Measures

ATR (14d)$0.16(5.6%)

StdDev (20d)0.17

Hist Vol38.7%(Moderate)

Volume Flow

VWAP$2.83

OBV86.9M

AD Line34.1M

CMF (20d)-0.317

Volume Metrics

Avg Vol (20d)43.7K

Vol Ratio0.6x

VWMA (20d)$3.09

Pivot Points

R3$2.91

R2$2.87

R1$2.84

Pivot Point$2.79

S1$2.76

S2$2.72

S3$2.68

Advanced Oscillators

TSI-18.91

Ultimate Osc24.0

KST-38.81

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$22,040	$7.49M	$37,000	$122,000	$122,000	$3.02M	$154,000	$50,881	$73,000	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	$-7,529,000	$7.49M	$37,000	$122,000	N/A	$3.02M	$154,000	$50,881	$73,000	N/A

Operating Expenses	$3.84M	$3.82M	$4.05M	$4.47M	$4.38M	$3.87M	$4.15M	$4.75M	$4.74M	$4.44M	$4.44M	$5.76M
R&D	$2.33M	$2.30M	$2.56M	$3.09M	$2.17M	$2.16M	$2.25M	$2.61M	$2.75M	$2.83M	$2.30M	$2.83M
SG&A	$1.51M	$1.52M	$1.19M	$1.38M	$2.21M	$1.71M	$1.59M	$2.13M	$1.98M	$1.61M	$1.86M	$2.93M
Operating Income	$-3,840,529	$-3,819,000	$-4,052,000	$3.02M	$-4,340,000	$-3,868,000	$-4,024,000	$-1,731,000	$-4,581,000	$-4,385,760	$-4,364,000	$-5,762,000

Interest Income	$31,000	$305,000	$5.43M	$2.69M	$30,000	$2.49M	$5.67M	$84,000	$41,000	$5.62M	$250,000	$72,000
Interest Expense	$160,771	$332,000	$1.12M	$1.36M	$241,000	$397,000	$1.70M	$385,211	$225,000	$246,000	$168,000	$182,000
Income Before Tax	$-3,927,406	$-3,845,000	$-6,173,000	$4.35M	$-5,026,000	$-1,772,000	$-3,904,000	$-2,031,000	$-6,397,000	$973,726	$-4,700,000	$-5,872,000
Income Tax Expense	$-203,709	$-216,000	$-256,000	$-265,000	$-195,000	$-192,000	$0	$-96,000	$-199,000	$-217,492	$-177,000	$-194,000

Net Income	$-3,723,696	$-3,629,000	$-5,918,000	$4.62M	$-4,831,000	$-1,580,000	$-3,629,000	$-1,935,000	$-6,198,000	$1.19M	$-4,523,000	$-5,678,000

EBITDA	$-3,840,529	$-3,513,000	$-8,285,000	$5.71M	$-4,785,000	$-1,375,000	N/A	$-1,647,000	$-6,172,000	$1.22M	$-4,474,000	$-5,490,000
EBIT	$-3,772,000	$-3,513,000	$-8,814,262	$3.02M	$-4,785,000	$-5,607,000	N/A	$-1,647,000	$-4,581,000	$1.18M	$-4,589,000	$-5,690,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about EVAX

News

Evaxion Biotech A/S (EVAX) Stock News Today

This article provides recent news for Evaxion Biotech A/S (EVAX), including its current stock price, market cap...

TradingKey•Aug 23, 2026 10:43 AM ET8/23/26•Neutral

Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)

This article highlights bullish analyst ratings for two healthcare companies: Evaxion Biotech (EVAX) and Ultragenyx Pharmaceutical (RARE). An H.C. Wainwright analyst reiterated a Buy rating for Evaxion Biotech with a $16...

The Globe and Mail•Aug 22, 2026 9:43 AM ET8/22/26•Bullish

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)

Two healthcare companies, Evaxion Biotech (EVAX) and Boston Scientific (BSX), have received bullish ratings from analysts. Evaxion Biotech was reiterated with a Buy rating and a $9.00 price target by Lake Street...

The Globe and Mail•Aug 22, 2026 9:42 AM ET8/22/26•Bullish

EVAXION BIOTECH ($EVAX) Releases Q2 2026 Earnings

This article announces that Evaxion Biotech ($EVAX) has released its Q2 2026 earnings report. Further details regarding the financial performance would be found within the full earnings document.

Moomoo•Aug 20, 2026 11:14 PM ET8/20/26•Neutral

Evaxion Expands Pipeline with EVX-05, an AI-Designed Off-the-Shelf Glioblastoma Vaccine

Evaxion has added EVX-05, an AI-designed, off-the-shelf therapeutic vaccine for glioblastoma, to its pipeline, while discontinuing the EVX-03 program to refocus R&D efforts. This new vaccine targets antigens derived from...

BioPharm International•Aug 17, 2026 11:40 PM ET8/17/26•Bullish

EVAX Valuation and Fair Value

P/E: -5.5x
Forward P/E: 3.6x
P/FCF: -0.1x
P/B: 0.1x

See GNG's fair value

EVAX Profitability: Margins, ROIC and FCF

Operating margin: -116.0%
Net margin: -115.5%
ROIC: -79.5%
ROE: -109.9%
FCF margin: -229.0%
FCF yield: -1505.1%

EVAX Competitors

Company	Ticker
Polyrizon Ltd. Ordinary Shares	PLRZ
Shuttle Pharmaceuticals Inc	SHPH
Seres Therapeutics Inc	MCRB
Immutep Ltd ADR	IMMP
PetMed Express Inc	PETS
Galecto Inc	GLTO
SRx Health Solutions Inc.	SRXH
Context Therapeutics Inc	CNTX

Sector: Healthcare

EVAX Analyst Ratings

Consensus: Buy
Analysts: 4
Strong Buy: 1
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

EVAX Bull Case vs Bear Case

Bear case

EVAX has a -115.5% net profit margin.
EVAX's quarterly revenue changed -100.0% year over year.

EVAX Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)
Average surprise: -578.0%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.01
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

Frequently Asked Questions About EVAX

Does EVAX pay dividends?

Evaxion Biotech AS (EVAX) does not currently pay a regular dividend.

What is EVAX's market cap?

Evaxion Biotech AS (EVAX) has a market capitalization of $25.26M with a current stock price of $2.80.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In